Risk perception in natalizumab-treated multiple sclerosis patients and their 
neurologists

Heesen, Christoph; Kleiter, Ingo; Nguyen, Franziska; Schäffler, Nina; Kasper, Jürgen; Köpke, Sascha; Gaissmaier, Wolfgang

doi:10.1177/1352458510379819

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

MPS-Authors

/persons/resource/persons139491

Gaissmaier, Wolfgang
Center for Adaptive Behavior and Cognition, Max Planck Institute for Human Development, Max Planck Society;
Harding Center for Risk Literacy, Max Planck Institute for Human Development, Max Planck Society;

External Resource

http://nbn-resolving.de/urn:nbn:de:bsz:352-280329
(Publisher version)

https://doi.org/10.1177/1352458510379819
(Publisher version)

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

There are no public fulltexts stored in PuRe

Supplementary Material (public)

There is no public supplementary material available

Citation

Heesen, C., Kleiter, I., Nguyen, F., Schäffler, N., Kasper, J., Köpke, S., et al. (2010). Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Multiple Sclerosis, 16(12), 1507-1512. doi:10.1177/1352458510379819.

Cite as: https://hdl.handle.net/11858/00-001M-0000-0024-F5FF-E

Abstract

There is no abstract available